middle.news
Why Did Imricor’s Revenue Plunge 69.5% Despite FDA Clearances?
7:52am on Wednesday 25th of February, 2026 AEDT
•
Healthcare
Read Story
Why Did Imricor’s Revenue Plunge 69.5% Despite FDA Clearances?
7:52am on Wednesday 25th of February, 2026 AEDT
Key Points
Total revenue fell 69.5% to $292,309 due to reduced product sales and clinical trial enrolments
Net loss improved to $25.3 million from $29.7 million, influenced by fair value adjustments
Strategic investments expanded European and US sales teams ahead of commercial launches
FDA granted 510(k) clearance for NorthStar Mapping System and Vision-MR Diagnostic Catheter in January 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
IMRICOR MEDICAL SYSTEMS (ASX:IMR)
OPEN ARTICLE